论文信息 - Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent - 字舞流文

Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent

V. Poindron | A. Korganow | O. Collange | L. Grunebaum | V. Gies | A. Guffroy | Y. Dieudonné | B. Nespola | X. Delabranche | L. Sattler | C. Tacquard | C. Kaeuffer | O. Vollmer | Lélia Grunebaum | Mirjana Radosavljevic | Yves Hansmann | Jean-Christophe Weber | Thierry Martin | Laurent Arnaud | Olivier Morel | Paul Michel Mertes | Lélia Grunebaum | Mirjana Radosavljevic | Jean-Christophe Weber | Olivier Morel | Paul Michel Mertes | Paul-Michel Mertes | O. Morel | Benoît Nespola | Y. Hansmann

[1] C. Frère,et al. Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. , 2020 .

[2] R. Clere-Jehl,et al. Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[3] J. Knight,et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 , 2020, Science Translational Medicine.

[4] K. Pasi,et al. Lupus Anticoagulant in Patients with Covid-19. Reply. , 2020, New England Journal of Medicine.

[5] R. Gooding,et al. Lupus Anticoagulant in Patients with Covid-19. , 2020, The New England journal of medicine.

[6] G. Nuovo,et al. Severe COVID-19: A multifaceted viral vasculopathy syndrome , 2020, Annals of Diagnostic Pathology.

[7] Y. Shoenfeld,et al. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine , 2020, Immunologic Research.

[8] H. Billett,et al. Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA network open.

[9] B. Mégarbane,et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? , 2020, Thrombosis Research.

[10] J. Mege,et al. Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID‐19 Severity , 2020, Arthritis & rheumatology.

[11] Z. Amoura,et al. High frequency of antiphospholipid antibodies in critically ill COVID‐19 patients: a link with hypercoagulability? , 2020, Journal of internal medicine.

[12] M. Ehrenfeld,et al. Covid-19 and autoimmunity , 2020, Autoimmunity Reviews.

[13] S. Sivapalaratnam,et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 , 2020, The New England journal of medicine.

[14] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[15] George M. Varghese,et al. Clinical management of COVID-19 , 2020, The Indian journal of medical research.

[16] J. Connors,et al. COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[17] B. Drénou,et al. Lupus anticoagulant is frequent in patients with Covid‐19 , 2020, Journal of Thrombosis and Haemostasis.

[18] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[19] M. Khamashta,et al. Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. , 2019, Seminars in arthritis and rheumatism.

[20] T. Ortel,et al. Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[21] Y. Shoenfeld,et al. Infectious origin of the antiphospholipid syndrome , 2005, Annals of the rheumatic diseases.